Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVADER in Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
NCT03822897Phase 2Active, not recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2019
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Canadian Cancer Trials Group. Primary endpoint: Event-free Survival at 2 years. Started Jun 2019; status: active, not recruiting.
02
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03822897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822897.